Skip to content

Natural Progesterone and Preterm Birth in Twins

Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00480402
Enrollment
290
Registered
2007-05-30
Start date
2006-01-31
Completion date
2007-06-30
Last updated
2013-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Keywords

preterm birth, progesterone, twins, Preterm birth in twin gestations

Brief summary

To assess the effectiveness of natural progesterone supplementation in preventing preterm births in twins.

Detailed description

Objective: To assess the effectiveness of natural progesterone supplementation in preventing preterm births in twins. Study Design: National multicenter randomized double blind controlled clinical trial. Setting: Six tertiary hospitals in the east of Spain (communities of Valencia and Murcia): Instituto Universitario IVI Valencia, Hospital Universitario La Fe (Valencia), Hospital Universitario Dr. Peset (Valencia), Hospital General Universitario (Alicante), Hospital Vega Baja de Orihuela (Alicante) y Hospital Virgen de la Arrixaca (Murcia). Population: 246 bichorionic biamniotic twin pregnant women divided in three groups according to the allocated randomized treatment: (I) placebo (N=82); (II) 200 mg progesterone (N=82); and (III) 400 mg progesterone (N=82). Methods: All participant women will self-administer two vaginal pessaries at bedtime containing the allocated treatment. Vaginal pessaries will be identical externally but will contain either placebo or 200 mg of natural progesterone (Laboratorios Effik, Madrid, Spain). The treatment will be applied from the 20th week until the 34th week (or until delivery if it occurred earlier). Control visits will be performed at 24, 28, 32 and 34 weeks. Pregnancies will be managed according to each local protocol. An external statistical analysis will be performed on intention to treat basis. Main outcome measure: Preterm birth rate (\<37 weeks). Secondary outcome measures: very preterm birth rate (\<32 weeks); cervical length measured by vaginal ultrasound at each control visit; need for tocolytic treatments; rate of preterm premature rupture of membranes; and perinatal morbidity and mortality. Estimated period of study: 2006-2008.

Interventions

DRUG200 mg of Progesterone

Administration of 200 mg of Progesterone

DRUG400 mg Progesterone

Administration of 400 mg Progesterone

DRUGPlacebo

Administration of a Placebo

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Bichorionic biamniotic twin pregnant women * = or \> 18 years old

Exclusion criteria

* Single pregnancy or monochorionic twin pregnancy or triplets * Chronic hepatic pathology, previous alterations in hepatic analysis during anti-contraceptive treatment; or gestational cholestasis in in previous pregnancies.Basal alterations in hepatic analysis profile. * Profylactic cerclage until week 14. * Basal alterations in renal analysis profile * Local allergy to micronized natural progesterone * Genital pathology not allowing for correct absorption of medication * Fetal anomoly diagnosed after sonograph week 12 and/or 20. * Smokers of more than 10 cigarettes/day * Consumers of illegal substances

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026